Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Fundamentals of Liver Disease- Hepatitis C

    Contains 65 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    HCV: Epidemiology and Screening
    Patient with new diagnosis of HCV (anti-HCV positive)
    Assessing severity of liver disease in HCV
    Management of the Patient with Chronic HCV
    Management of the Chronic HCV Patient with co-morbid and other conditions
    Antiviral treatment of the patient with HCV infection
    Management of patients with HCV who have achieved a virological "cure"
    The Pediatric patient with HCV

    COMPONENTS
    Online:
    8 online interactive, narrated modules 30 to 40 minutes in length
    Pre- and post-test questions for each module

    Original release date: April 10, 2014
    Review date:July 1, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes

    Copyright:
    All faculty in this activity have given their permission for publication OR
    ©2017 AASLD

    Contact Information
    For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
    For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.

    John W. Ward

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Jordan J. Feld

    Sanjeev Arora

    Raymond T. Chung

    Michael W. Fried

    Andrew J. Muir

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

    Kathleen B. Schwarz

    Learning Objective:

    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    CME

    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse

    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 4.0 contact hours.

    Maintenance of Certification (MOC) Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    How to Earn/Claim MOC

     

    •    For each module that you wish to claim MOC points for you must:

     

                o    Complete the pre-test

     

                o    Review/watch the slides in the presentation

     

                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

     

                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

     

    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

     

    •    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The faculty, organizers and reviewers have reported the following disclosures:

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix, Norgine and Alfa-Wasserman 
    Grant/Research Support: Grifols, Salix

    Thomas Boyer, MD
    Faculty
    Consulting: Ikaria
    Grant/Research Support: Ikaria

    Michael Fallon, MD
    Faculty
    Nothing to disclose

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Paul Martin, MD
    Faculty
    Grant/Research Support: AbbVie and Genfit

    Puneeta Tandon, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD
    Faculty
    Speakers' Bureau: L.W. Gore & Associates

    Sanjeev Arora, MD
    Organizer
    Advisory Committee: CDC Advisory Committee - Hep C
    Grant/Research Support: Gilead, Beckman Coulter, Merck, AbbVie

    Lauren Beste, MD
    Organizer
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Organizer, Faculty
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Organizer
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Organizer
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Organizer
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Organizer
    Nothing to disclose

    Norah Terrault, MD
    Organizer
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Organizer
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Reviewer
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Reviewer
    Nothing to Disclose

    Gene Y Im, MD
    Reviewer
    Nothing to Disclose

    Iris W Liou, MD
    Reviewer
    Nothing to Disclose

    Jesse M Civan, MD
    Reviewer
    Education: Merck

    HoChong Gilles, FNP
    Reviewer
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Reviewer
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Reviewer
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Reviewer
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Reviewer
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Fundamentals of Liver Disease- Cirrhosis

    Contains 74 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    Does My Patient Have Cirrhosis?

    Natural History of Cirrhosis and General Management of the Compensated Patient

    Varices and Variceal Hemorrhage

    Ascites

    Hyponatremia and Hepatorenal Syndrome

    Hepatic Encephalopathy

    Infections in cirrhosis

    Pulmonary complications in the patient with cirrhosis

    Does my patient with cirrhosis need to be referred for liver transplant?

     

    COMPONENTS

    Online presentations comprised of PowerPoint slides and accompanying audio and online pre- and post-tests and evaluations:

    -9 online interactive, narrated modules 20 to 40 minutes in length

    -Pre- and post-test questions for each module

    Original release date: July 20, 2015
    Expiration date: July 19, 2017
    Review date: January 1 - November 30, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes

     

    Copyright:

    All faculty in this activity have given their permission for publication OR

    ©2017 AASLD

     

    Contact Information

    For questions on CE credit for this activity, email Certificate@AmedcoEmail.com

    For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org

    Patrick S. Kamath

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Juan G. Abraldes

    Florence Wong

    Thomas D. Boyer

    Dr. Thomas D. Boyer is currently Professor of Medicine and Director of the Liver Research Institute at the University of Arizona School of Medicine in Tucson, Arizona. He has a longstanding interest in the complications of portal hypertension including bleeding varices, ascites, and hepatorenal syndrome. Dr. Boyer has published a number of papers in each of these areas of interest.

    Jasmohan S. Bajaj

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

    Michael B. Fallon

    Paul Martin

    Learning Objective:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    CME

    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse

    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 4.5 contact hours.

    MOC

    Maintenance of Certification (MOC) Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    How to Earn/Claim MOC

     

    •    For each module that you wish to claim MOC points for you must:

     

                o    Complete the pre-test

     

                o    Review/watch the slides in the presentation

     

                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

     

                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

     

    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

     

    •    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The faculty, organizers and reviewers have reported the following disclosures:

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix, Norgine and Alfa-Wasserman 
    Grant/Research Support: Grifols, Salix

    Thomas Boyer, MD
    Faculty
    Consulting: Ikaria
    Grant/Research Support: Ikaria

    Michael Fallon, MD
    Faculty
    Nothing to disclose

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Paul Martin, MD
    Faculty
    Grant/Research Support: AbbVie and Genfit

    Puneeta Tandon, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD
    Faculty
    Speakers' Bureau: L.W. Gore & Associates

    Sanjeev Arora, MD
    Organizer
    Advisory Committee: CDC Advisory Committee - Hep C
    Grant/Research Support: Gilead, Beckman Coulter, Merck, AbbVie

    Lauren Beste, MD
    Organizer
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Organizer, Faculty
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Organizer
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Organizer
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Organizer
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Organizer
    Nothing to disclose

    Norah Terrault, MD
    Organizer
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Organizer
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Reviewer
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Reviewer
    Nothing to Disclose

    Gene Y Im, MD
    Reviewer
    Nothing to Disclose

    Iris W Liou, MD
    Reviewer
    Nothing to Disclose

    Jesse M Civan, MD
    Reviewer
    Education: Merck

    HoChong Gilles, FNP
    Reviewer
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Reviewer
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Reviewer
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Reviewer
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Reviewer
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Fundamentals of Liver Disease - Abnormal Liver Tests 2.0

    Contains 65 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    Currently, there is an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    Anatomy and Physiology of the Liver
    Liver Tests
    Acute Hepatocellular Injury
    Acute Cholestatic Liver Injury
    Chronic Hepatocellular Injury
    Chronic Cholestatic Injury
    Interpretation of Viral Serologies in Acute and Chronic Hepatitis
    Outcomes of Patients with Abnormal Liver Tests

    Release date: November 5, 2019
    Expiration date: November 4, 2022
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™
    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
    Continuing Education (CE): For a maximum of 4.00 Contact Hour

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    -8 online, narrated modules 25 to 30 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CE or CME credit offering

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim CE or CME and or MOC.

    COPYRIGHT
    All faculty in this activity have given their permission for publication. ©2019 AASLD 

    CONTACT INFORMATION
    For questions on CME and or MOC content or LiverLearning®, contact online_education@aasld.org
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    LEARNING OBJECTIVES

    · Discuss normal liver function and anatomy.
    · Identify routine liver tests, when to order and how to interpret results.
    · Recognize acute hepatocellular injury and cholestatic injury based on liver tests results.
    · Recognize chronic hepatocellular injury and chronic cholestatic injury based on liver tests results.
    · Describe outcomes for patients with abnormal liver tests.

    This enduring material was developed for the following:

    • Hepatologists
    • Gastroenterologists
    • Nurses
    • Nurse Practitioners
    • Pharmacists
    • Physician Assistants
    • Transplant Coordinators
    • Surgeons
    • Fellows/Trainees
    • Primary Care Physicians
    • Other healthcare providers

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.00 AMA PRA Category 1 Credits™
    Maintenance of Certification (MOC): For a maximum of 4.00 MOC Points
    Continuing Education (CE): For a maximum of 4.00 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS
    Continuing Medical Education (CME) The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS
    Physicians and other health care professionals for a maximum of 4.00 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by November 4, 2022

    CLAIMING ABIM MOC POINTS 
    Physicians seeking ABIM MOC credit must complete the enduring material by November 4, 2022. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through December 2022 for individuals who successfully complete MOC.

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.00 contact hours for this enduring continuing education material must be completed by November 4, 2022

    HOW TO EARN AND CLAIM MOC POINTS
    For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-test

                 o    Watch video presentation

                 o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Tamar H. Taddei

    Tamar Taddei, MD, FAASLD is an Associate Professor of Medicine in the Section of Digestive Diseases at Yale University and staff hepatologist at the VA Connecticut Healthcare System in West Haven, CT. She directs the liver cancer program at VA Connecticut.  She is Associate Director of the MD/PhD Program at Yale School of Medicine.  She is a board certified gastroenterologist with a certificate of added qualification in transplant hepatology.  Her clinical interests include end stage liver disease, liver transplantation, and liver cancer.  She leads the VA Connecticut’s Cancer Care Tracking System Team, a group that has facilitated early detection of cancer and timely access to comprehensive cancer care through innovation in systems of care and technology.  She is co-PI of the Veterans Outcomes and Costs Associated with Liver disease (VOCAL) Study Group.

    Hugo E. Vargas

    Hugo E. Vargas, MD, FAASLD is a Mayo Clinic Consultant in the Department of Gastroenterology and Hepatology and the Mayo Clinic Transplantation Center. He is the Medical Director for the Office of Clinical Research – Arizona, and a Professor of Medicine in the Mayo Clinic Alix School of Medicine. Dr. Vargas is the Chair of the Clinical Research Subcommittee, and the Vice Chair of the Arizona Research Operations Management Team.  

    Dr. Vargas has authored or coauthored more than 125 peer-reviewed articles. He is a Fellow of the AASLD, AGA, ACG, ASGE and ACP. He has been active in AASLD and has chaired the Annual Meeting Education Committee, Ethics Commiteee and co-chaired the AASLD/IDSA HCV group from 2016 to 2018. 

    Oren K. Fix

    Oren K. Fix, MD, MSc, FAASLD is Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle. He earned his medical degree at SUNY Buffalo School of Medicine and a masters degree in Epidemiology from Boston University School of Public Health. He completed his Internal Medicine residency and Gastroenterology fellowship at Boston University and Transplant Hepatology fellowship at University of California San Francisco (UCSF). Dr. Fix was a site principal investigator in the NIH-funded Acute Liver Failure Study Group for 8 years at University of Washington and UCSF. He has published over 45 peer-reviewed manuscripts and book chapters, many on the topic of acute liver failure.

    Victor J. Navarro

    Victor J. Navarro, MD, MHCM, FAASLD earned his Doctor of Medicine degree from the Pennsylvania State College of Medicine and completed medical residency followed by chief residency in Internal Medicine at Temple University.  Thereafter, he obtained fellowship training in Gastroenterology, Hepatology, and Hepatobiliary Endoscopy at Yale University.  In 1994, Dr. Navarro joined the faculty of the Yale University School of Medicine as an Assistant Professor of Medicine and Epidemiology and the Director of its Liver Failure and Transplantation service. He was also the Director of the State of Connecticut Emerging Infections Program Liver Study Unit.  His scholarly work while at Yale focused on the population-based epidemiology of chronic liver disease. In 2019, Dr. Navarro earned his Masters in Healthcare Management from Harvard University.

    As a mentor, Dr. Navarro has been directly responsible for the scholarly and clinical training of many young and mid-career health professionals and academicians.  Dr. Navarro’s chief sources of research funding are the National Institutes of Health as an investigator for the U.S. Drug Induced Liver Injury Network (DILIN), and the Patient Centered Outcomes Research Institute for his study of Palliative Care in Patients with End Stage Liver Disease.

    Manal F. Abdelmalek

    Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Scottsdale AZ and Rochester, MN and obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida.  Since first reporting on nonalcoholic fatty liver disease (NAFLD) as a cause of cryptogenic cirrhosis over 20 years ago, her clinical and research area of interest have been in the field of NAFLD, its associated risk factors for disease acquisition and progression and novel approaches to treatment. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD.  She collaborates extensively to translate new compounds to first-in-man clinical studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression.  Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease.  She is a standing member of NASH Clinical Research Network (NASH CRN).  She has over 150 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD. 

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    Mindie H. Nguyen

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Meena B. Bansal

    Meena B. Bansal, MD, FAASLD is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She did her internship and residency at Cornell Medical School and then completed Gastroenterology Fellowship at the University of Pennsylvania in 2001.

    Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. In 2013, she became the Medical Director of all Hospital-based Clinics at Mount Sinai. In this latter role she developed an interest in population health and the challenges of the evolving health care landscape. Over the past 5 years, her focus has also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Tamar H. Taddei, MD, FAASLD
    Faculty
    Grant/research support: Bayer Healthcare Pharmaceuticals 
    Consulting: Onyx Pharmaceuticals

    Hugo E. Vargas, MD, FAASLD
    Faculty
    Nothing to disclose

    Oren K. Fix, MD, MSc, FAASLD
    Faculty
    Nothing to disclose

    Victor J. Navarro, MD, MHCM, FAASLD
    Faculty
    Nothing to disclose

    Manal F. Abdelmalek, MD, MPH
    Faculty
    Grant/research support: Gilead Sciences, TaiwanJ, NGM, Bristol-Myers Squibb, Genfit, Allergan, Madrigal, Conatus, Boehringer-Ingelhiem, Promethues, Galmed, Novartis, Enanta and Intercept Pharmaceuticals
    Consulting:  TaiwanJ, Bristol-Myers Squibb, Siemens Heathineers, Prometic, and Inventiva

    Cynthia Levy, MD, FAASLD
    Faculty
    Grant/research support: Gilead Sciences, Intercept, CymaBay, Novartis, GSK, Lilly, Enanta, Genkyotex, Genfit, Durect, HighTide, Alnylam
    Consulting: Cara Therapeutics, Target PharmaSolutions, Pliant, GSK
    Associate Editor: Liver Transplantation
    Royalities up-to-date

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
    Faculty
    Honoraria and research support: Janssen Pharmaceuticals, Gilead Sciences, Spring Bank, Intercept, Anylam, Pfizer and Novartis

    Meena B. Bansal, MD, FAASLD
    Faculty
    Nothing to disclose

    Sanjeeva Arora, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author

    Guadalupe Garcia-Tsao, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Advisory Board: Intercept, Conatus
    Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
    Research Grants: Intercept

    Leslie Hayes
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Minhhuyen Nguyen, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Vicki Shah, PA
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

    Raj Vuppalanchi, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Covence

    Susan Zapatka, MSN
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton
    AASLD Staff
    Nothing to disclose

    Janeil Klett
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Clinical Hepatology Update 2018

    Contains 17 Component(s), Includes Credits

    The goal of the 2018 Clinical Hepatology Update is to allow medical professionals the opportunity to review the up-to-date diagnosis and management of a variety of liver diseases with experts and leaders in the field of Hepatology. This course will also cover ongoing research in a variety of liver related topics which will potentially have significant impact on the future practice of Clinical Hepatology. The content features academic leaders in Hepatology who are actively contributing to these advances.

    The goal of the 2018 Clinical Hepatology Update is to allow medical professionals the opportunity to review the up-to-date diagnosis and management of a variety of liver diseases with experts and leaders in the field of Hepatology. This course will also cover ongoing research in a variety of liver related topics which will potentially have significant impact on the future practice of Clinical Hepatology. The content features academic leaders in Hepatology who are actively contributing to these advances.


    Core Competencies:  

    • Patient-centered Care
    • Work in Interdisciplinary Teams
    • Evidence-based Practice
    • Quality Improvement
    • Patient Care
    • Medical Knowledge
    • Practice Based Learning and Improvement 
    • Cognitive Expertise  

    Program Chairs

    • Hari S. Conjeevaram, MD, MS
    • Coleman I. Smith, MD, FAASLD
    • Elizabeth K. Goacher, PA-C, MHS
    • April G. Morris, FNP

    Components

    Learners will: 

    • Listen to 6 self-directed recorded sessions (90 - 135 minutes in length) while following along with visual slides
    • Take a post-activity quiz for each session
    • Answer evaluation questions

    All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    Release Date: September 20, 2018
    Expiration Date: September 19, 2020


    Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

    Hari Conjeevaram (Moderator)

    Coleman I. Smith (Moderator)

    Elizabeth K. Goacher (Moderator)

    Zobair M. Younossi

    Robert J. Fontana

    Victor J. Navarro

    Victor J. Navarro, MD, MHCM, FAASLD earned his Doctor of Medicine degree from the Pennsylvania State College of Medicine and completed medical residency followed by chief residency in Internal Medicine at Temple University.  Thereafter, he obtained fellowship training in Gastroenterology, Hepatology, and Hepatobiliary Endoscopy at Yale University.  In 1994, Dr. Navarro joined the faculty of the Yale University School of Medicine as an Assistant Professor of Medicine and Epidemiology and the Director of its Liver Failure and Transplantation service. He was also the Director of the State of Connecticut Emerging Infections Program Liver Study Unit.  His scholarly work while at Yale focused on the population-based epidemiology of chronic liver disease. In 2019, Dr. Navarro earned his Masters in Healthcare Management from Harvard University.

    As a mentor, Dr. Navarro has been directly responsible for the scholarly and clinical training of many young and mid-career health professionals and academicians.  Dr. Navarro’s chief sources of research funding are the National Institutes of Health as an investigator for the U.S. Drug Induced Liver Injury Network (DILIN), and the Patient Centered Outcomes Research Institute for his study of Palliative Care in Patients with End Stage Liver Disease.

    Lindsay King

    Amol S. Rangnekar

    Jessica L. Mellinger

    Stephen H. Caldwell

    Dr. Stephen Caldwell is a hepatologist specializing in a nonalcoholic steatohepatitis (NASH), including its relationship to so-called cryptogenic cirrhosis, ethnic and familial relationships and the role of mitochondrial dysfunction in the disease. He and his colleagues pioneered work on cellular ballooning and the role of small fat droplets in NASH and have also worked extensively with cyanoacrylates in the treatment of gastric variceal bleeding. He is overseeing a number of treatment trials for NASH and related liver fibrosis and is closely involved with a network of physicians and scientists working with coagulation disorders in liver disease. In 1992, he joined the faculty at UVA, helping to develop the hepatology program. Now a professor of medicine in the Division of Gastroenterology and Hepatology at UVA, Dr. Caldwell is board-certified in internal medicine and gastroenterology.

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    Matthew R. Kappus

    April G. Morris

    Cynthia Moylan

    Mishal Mendiratta-Lala

    Christine Hsu

    Catherine Frenette

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Michael B. Fallon

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

    Mitchell L. Shiffman

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Upon completion of this activity, learners will be able to: 

    • Discuss the management of patients with a variety of common problems in liver disease.
    • Become familiar with ongoing advances in hepatology and their potential application to clinical practice.
    • Implement evidence-based treatment in a variety of liver diseases

    • Hepatologists 
    • Gastroenterologists    
    • Nurse Practitioners
    • Physician Assistants  
    • Pharmacists               
    • Transplant Coordinators
    • Surgeons        
    • Fellows/Trainees        
    • Other physicians Specify: Primary care MDs
    • Other healthcare professionals Specify: Clinical researchers in the field of liver disease

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement. All sessions must be viewed and all post-tests must be completed successfully to earn credits or points for this activity. Please note, no partial credits or points will be given.  

    CME 

    Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation AASLD designates this enduring activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement 

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    “Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 12.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.”

    MOC Points Process

    Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.

    CE Credit

    image

    Nurses

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 12.25 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.  


    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The organizers and faculty have reported the following disclosures:

    Hari S. Conjeevaram, MD, MS
    Faculty
    Nothing to disclose

    Elizabeth K. Goacher, PA-C, MHS
    Faculty
    Advisory Boards and/or Review Panels: AbbVie Pharmaceuticals, Gilead Pharmaceuticals
    Speakers' Bureau: AbbVie Pharmaceuticals; Gilead Pharmaceuticals

    Robert J. Fontana, MD, FAASLD
    Faculty
    Consulting: Alynam Pharmaceuticals
    Grants/Research Support: BMS, Gilead, Abbvie

    Victor J. Navarro , MD, FAASLD
    Faculty
    Nothing to disclose

    Lindsay Y. King, MD 
    Faculty
    Nothing to disclose

    Amol S. Rangnekar, MD
    Faculty
    Nothing to disclose

    Michael B. Fallon, MD, FAASLD
    Faculty
    Nothing to disclose

    Stephen H. Caldwell, MD, FAASLD
    Faculty
    Advisory Committees or Review Panels: Gencia
    Grants/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed
    Royalties: Halyard

    Elliott B. Tapper, MD
    Faculty
    Grants/Research Support: Valeant, Gilead 

    Matthew R. Kappus, MD 
    Faculty
    Nothing to disclose

    Jessica Mellinger, MD
    Faculty
    Grants/Research Support: Salix Pharmaceuticals

    April G. Morris , FNP
    Faculty
    Advisory Boards and/or Review Panels: AbbVie, Inc., Merck & Co.
    Speakers' Bureau: Gilead, AbbVie, Inc.

    Zobair M. Younossi , MD, MPH, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
    Consulting: Gilead, Intercept

    Cynthia A. Moylan, MD
    Faculty
    Grants/Research Support: TaiwanJ Pharmeceuticals, Madrigal Pharmaceuticals, Conatus

    Mishal Mendiratta-Lala, MD
    Faculty
    Nothing to disclose

    Christine Hsu, MD
    Faculty
    Nothing to disclose

    Catherine T. Frenette, MD
    Faculty
    Advisory Boards and/or Review Panels: Bayer, Intercept
    Speakers' Bureau: Bayer, Gilead 

    Puneeta Tandon, MD, FRCP
    Faculty
    Nothing to disclose

    Mitchell L. Shiffman, MD, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: Abbvie, BMS, Gilead, Intercept, Merck, Salix
    Grants/Research Support: Abbvie, BMS, Conatus, CymaBay, Exalenz, Galectin, Genfit, Intercept, Immuron, Merck, NGMBio, Novartis, Shire
    Speakers' Bureau: Abbvie, Bayer, BMS, Daiichi Sankyo, Gilead, Intercept, Merck

    Nancy Reau, MD, FAASLD
    Faculty
    Advisory Boards and/or Review Panels: AbbVie
    Consulting: Gilead, Abbott, Merck 

    Coleman I. Smith, MD, FAASLD
    Faculty
    Adisory Board and/or Review Panels: BMS, Dova
    Grants/Research Support: Promethius, Genfit, Intercept, Conatus, Gilead, Abbvie, BMS
    Speakers' Bureau: Gilead, Abbvie

    Norah Terrault, MD, PhD
    Faculty
    Advisory Committees or Review Panels: Merck, Intercept, Conatus; Consulting: CCO Hepatitis, Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc.
    Grants/Research Support: AbbVie, Biotest, Eisai, Gilead, BMS, Merck, Allergan
    Royalties: UpToDate

    Anne Wrobel
    Staff Liason
    Nothing to disclose

    Sheryl Morgan, CE Coordinator
    Amedco Staff
    Nothing to disclos

    Acknowledgement of Financial or In-Kind Commercial Support

    No financial or in-kind commercial support was received for this educational activity.

  • AASLD 2016 Transplant Hepatology Review Course

    Contains 20 Component(s)

    This one and one-half day symposium will consist of didactic lectures and case presentations aimed at the practicing hepatologist preparing to take the certification and re-certification exam in Transplant Hepatology.

    This one and one-half day symposium will consist of didactic lectures and case presentations aimed at the practicing hepatologist preparing to take the certification and re-certification exam in Transplant Hepatology.  

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Anna S. Lok

    Naga P. Chalasani

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    Josh Levitsky

    Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.

    Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.

    William M. Lee

    Jaquelyn Fleckenstein

    Michael R. Lucey

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Elizabeth Pomfret

    Sarah J. Diamond

    Jorge A. Marrero

    Philip Rosenthal

    Jay A. Fishman

    Mark W. Russo

    Michael S. Kriss

  • Fundamentals of Liver Disease- Hepatitis B

    Contains 57 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

     

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    HBV: Epidemiology and Screening
    Patient with positive Hepatitis B serologies
    Natural history of HBV and identification of treatment candidates
    Management of the Chronic HBV patient with co-morbid and other conditions
    Antiviral treatment of the Patient with Chronic HBV
    Prevention of HBV infection
    Hepatitis B in the Pediatric Patient

    COMPONENTS
    Online:
    7 online interactive, narrated modules 30 to 40 minutes in length
    Pre- and post-test questions for each module

    Original release date: April 10, 2014
    Review date: July 1, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes


    Copyright:
    All faculty in this activity have given their permission for publication OR
    ©2017 AASLD

    Contact Information
    For questions on CE credit for this activity contact Certificate@AmedcoEmail.com
    For questions on MOC/CME/CE content or the activity web site, contact education@aasld.org.

    Marc G. Ghany

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Marion G. Peters

    Anna S. Lok

    Brian J. McMahon

    Maureen M. Jonas

    Learning Objective:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    CME

    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse

    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 3.5 contact hours.

    Maintenance of Certification (MOC) Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    How to Earn/Claim MOC

     

    •    For each module that you wish to claim MOC points for you must:

     

                o    Complete the pre-test

     

                o    Review/watch the slides in the presentation

     

                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

     

                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

     

    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

     

    •    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The organizers and faculty have reported the following disclosures:

    Marc Ghany, MD
    Faculty
    Nothing to disclose

    Tram Tran, MD
    Faculty
    Grant/Research Support: Bristol-Myers Squibb, Gilead; Consulting: Bristol-Myers Squibb, Gilead
    Advisory Committee or Review Panels: Bristol-Myers Squibb, Gilead

    Marion Peters, MD
    Faculty
    Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

    Anna S.F. Lok, MD
    Faculty
    Grant/Research Support: BMS and Gilead

    Brian McMahon, MD, FAASLD
    Faculty
    Grant/Research Support:  Gilead Sciences- grant received by department at institution and not directly.

    Maureen Jonas, MD
    FacultyAdvisory Committee or Review Panels: Served as chair of DSMB for Gilead
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Roche, Echosens (equipment only)
    Consulting: AbbVie

    Lauren Beste, MD
    Organizer
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer, Faculty
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Organizer
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Organizer
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Organizer
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Organizer
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Organizer
    Nothing to disclose

    Norah Terrault, MD
    Organizer, Faculty
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Organizer
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Reviewer
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Reviewer
    Nothing to Disclose

    Gene Y Im, MD
    Reviewer
    Nothing to Disclose

    Iris W Liou, MD
    Reviewer
    Nothing to Disclose

    Jesse M Civan, MD
    Reviewer
    Education: Merck

    HoChong Gilles, FNP
    Reviewer
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Reviewer
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Reviewer
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Reviewer
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Reviewer
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Role of Diet and Exercise in the Management of NAFLD

    Contains 1 Component(s) Recorded On: 04/24/2018

    Webinar hosted by the Non-Alcoholic Fatty Liver Disease Special interest group April 24, 2018.

    In this webinar, we will review the role of diet and exercise in the management of NAFLD. Specifically, we will overview the data in support of specific nutritional programs and physical activity regimens that have been shown to improve histologic components of NAFLD and NASH. Lastly, we will outline the remaining knowledge gaps and barriers related to lifestyle interventions in the treatment of NAFLD/NASH.

    Michelle Long

    Dr. Long is an Assistant Professor of Medicine at the Boston University School of Medicine in Boston Massachusetts and an investigator at the Framingham Heart Study. Dr. Long is hepatologist and physician scientist with a clinical specialization in non-alcoholic fatty liver disease (NAFLD). Her primary research focus is in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD. 

    Monica A. Konerman

    Dr. Monica Konerman is a Clinical Lecturer in Internal Medicine in the Division of Gastroenterology and Hepatology at the University of Michigan. She is board certified in Transplant Hepatology and conducts clinical and health services research. Her areas of interest include NAFLD/NASH, liver transplant, and clinical risk prediction.

    Rohit Loomba (Moderator)

    Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.

  • Cost-Effective Approach to Evaluation of Abnormal Liver Enzymes

    Contains 1 Component(s) Recorded On: 04/19/2018

    Webinar hosted by the Clinical Practice Special interest group April 19, 2018.

    This webinar will focus on best practices regarding evaluation of the patient presenting with abnormal liver enzymes. The focus will be not only on testing needed to arrive at the appropriate diagnosis, but also how to approach testing to minimize costs. This is an essential part of the daily practice for hepatologists and gastroenterologists.

    Vinay Sundaram (Moderator)

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

  • Surgical Risk in the Portal Hypertensive Patient

    Product not yet rated Contains 1 Component(s) Recorded On: 03/07/2018

    Webinar hosted by the Portal Hypertension Special Interest group on March 7, 2018.

    The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.

    Brett E. Fortune (Moderator)

    Dr. Brett E. Fortune, MD, MSc, is a Transplant Hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation. His research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

    Theo Heller (Moderator)

    Dr. Heller is a senior clinical investigator at the National Institutes of Health where he heads the Translational Hepatology Section. His research focuses on liver disease progression with a particular focus on non-cirrhotic portal hypertension as a model for all patients with portal hypertension. He is focused on enhancing the clinical care of patients with portal hypertension while elucidating mechanisms that underlie the development of portal hypertension due to any etiology. His research encompasses translational and clinical techniques with the ultimate aim of ensuring superb outcomes for patients with liver disease.

     

    Lawrence S. Friedman

    Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.

    Manuel I. Rodriguez-Davalos

    Dr. Manuel Rodriguez-Davalos is currently the surgical director of pediatric liver transplantation at Primary Children’s Hospital in Salt Lake City, Utah, and the medical director of the living donor liver transplantation program at Intermountain Medical Center. He was an Associate Professor of Surgery and Pediatrics at the Yale School of Medicine, where he was also the Director of Pediatric Transplantation at the Yale New Haven Transplantation since 2012. He was the liver review board primary representative for CTYN and served as Region 1 representative in the OPTN/UNOS Pediatric Transplantation Committee. He has been involved in research of ischemia reperfusion injury and the development of novel means for perfusion and preservation techniques to improve graft quality, expand the donor pool. His projects during the past 5 years in translational research involve the use of partial grafts and extended criteria for donation in liver transplantation, preservation techniques for decreasing ischemia-reperfusion injury in intestinal and liver grafts. He is collaborating with the Yale School of Engineering on the design and use of new perfusion devices for organ preservation and research.

  • Acute on Chronic Liver Failure in Children

    Contains 1 Component(s) Recorded On: 02/15/2018

    Webinar hosted by the Pediatric Liver Disorders Special Interest group on February 15, 2018.

    Acute on chronic liver failure is increasingly understood in adults, less so in children. The aims of this Webinar are to increase understanding about the causes of acute liver decompensation in children with chronic, compensated liver disease, and the acute-care management of ACLF. 

    John Bucuvalas (Moderator)

    John Bucuvalas MD, FAASLD is Professor of Pediatrics and has a broad background in transplant hepatology. He has published broadly on outcomes following liver transplantation, acute liver failure and adherence after liver transplantation.  He has  established strong ties with pediatric solid organ transplant community and with the liver transplant community thru SPLIT, NIH, AST and UNOS. 

    Simon P. Horslen

    Simon Horslen MB ChB FRCPCH FAST FAASLD is a Professor in the Division of Pediatric Gastroenterology, Hepatology & Nutrition at Seattle Children’s Hospital and the University Of Washington School Of Medicine. He is Medical Director for Solid Organ Transplantation at Seattle Children’s Hospital. He is a Pediatric Hepatologist and Transplant Physician with many years’ experience of liver and intestinal transplantation in children.  Dr Horslen participates in several multicenter research studies including SPLIT (Studies in Pediatric Liver Transplantation), PALF (Pediatric Acute Liver Failure) and ChiLDREN (Children’s Liver Disease Research Network).

    Akash Deep

    Dr. Akash Deep is the Director of the Pediatric Intensive Care Unit at King's College Hospital, London; one of the largest pediatric liver transplant centers in the world. Dr. Deep is the Chair for the Renal/CRRT Section of European Society of Pediatric and Neonatal Intensive Care Society (ESPNIC). He is the co-Chair for the Science and Education Committee of Pediatric Intensive Care Society (PICS) of UK. His special interests include acute liver failure, acute on chronic liver failure, liver assist devices in liver failure, acute kidney injury, CRRT and hemodynamics in septic shock.